NeoStem Adds Distinguished Orthopaedic Surgeon to its Medical Advisory Board
Dr. Thomas Einhorn has Clinical Experience Using Innovative Adult Stem Cell Therapies for Orthopedic Ailments
NEW YORK, Aug. 4 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that it has appointed Thomas Einhorn, M.D., Chairman of Orthopaedic Surgery at Boston University to its Medical Advisory Board. Thomas A. Einhorn, M.D. is Chairman of the Department of Orthopaedic Surgery and Professor of Orthopaedic Surgery, Biochemistry and Biomedical Engineering at Boston University. A graduate of Rutgers University and Cornell Medical College, he completed his internship at the Hospital of the University of Pennsylvania, orthopaedic residency at St. Luke's – Roosevelt Hospital in New York City, and a fellowship at the Hospital for Special Surgery. His professional focus is on the repair and regeneration of bone and cartilage using autologous adult stem cells, reconstructive surgery of the hip and knee, and the treatment of metabolic bone disease. He has authored over 200 peer-reviewed articles during his career to date.
Dr. Einhorn has served as Chairman of the Orthopaedics and Musculoskeletal Study Section of the National Institutes of Health, President of the Orthopaedic Research Society, President of the International Society for Fracture Repair, Chairman of both the Committee on Examinations and the Council on Research and Scientific Affairs of the American Academy of Orthopaedic Surgeons and a trustee of the Orthopaedic Research and Education Foundation and the National Osteoporosis Foundation. His awards include the Marshall R. Urist Award and the Alfred R. Shands, Jr. Award from the Orthopaedic Research Society, the Kappa Delta Award from the American Academy of Orthopaedic Surgeons, the Dr. Marian Ropes Physician Achievement Award from the Arthritis Foundation and the Marshall Schiff Award from the American College of Rheumatology. He is Deputy Editor for Current Concepts Reviews for The Journal of Bone and Joint Surgery, and serves on the Editorial Boards of The Journal of Bone and Mineral Research, Journal of Orthopaedic Research and Bone. Since 1997, he has been listed in Best Doctors.
Wayne A. Marasco, M.D., Ph.D., Chairman of NeoStem's Advisory Boards, said, "We are extremely pleased to have Dr. Einhorn join our medical advisory board. His in-depth understanding of orthopaedic injuries and the use of adult stem cells to regenerate damaged bone and cartilage will be a tremendous asset in our development of applications of adult stem cells for orthopedic injuries."
Dr. Einhorn commented, "I am excited to join the Medical Advisory Board of an innovative, forward-looking company like NeoStem and be part of the team of experts to help advance stem cell technologies in the field of orthopaedics and assist in developing VSEL™ Technology applications for orthopaedic disease. Not only has the Company put together a promising base of technologies for future stem cell treatment in orthopaedics, cardiac, skin rejuvenation and the treatment of wounds but it continues to partner with experts in other areas to facilitate meaningful R&D. This should encourage people to collect, process and store their stem cells through NeoStem's existing network of collection centers in anticipation of a variety of future personalized medicine applications."
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include the future of VSEL TM Technology as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic and other filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
NeoStem, Inc. |
|
Robin Smith, CEO |
|
Phone: +1 (212) 584-4174 |
|
E-mail: [email protected] |
|
SOURCE NeoStem, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article